| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/20/2001 | WO2001068663A1 Nucleoside compounds and uses thereof |
| 09/20/2001 | WO2001068662A1 Method of preparing clarithromycin of form ii crystals |
| 09/20/2001 | WO2001068660A1 Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| 09/20/2001 | WO2001068654A2 Tubulin binding ligands and corresponding prodrug constructs |
| 09/20/2001 | WO2001068653A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | WO2001068652A1 Condensed imidazoles as histamine h3 receptor ligands |
| 09/20/2001 | WO2001068651A1 Condensed imidazoles as histamine h3 receptor ligands |
| 09/20/2001 | WO2001068648A1 Substituted beta-carbolines with ikb-kinase inhibiting activity |
| 09/20/2001 | WO2001068646A1 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 09/20/2001 | WO2001068643A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | WO2001068637A2 Method for the preparation of tetrahydrobenzothiepines |
| 09/20/2001 | WO2001068634A1 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity |
| 09/20/2001 | WO2001068633A1 2-phenylpyran-4-one derivatives |
| 09/20/2001 | WO2001068632A1 Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | WO2001068631A1 Method for the preparation of citalopram |
| 09/20/2001 | WO2001068630A1 Method for the preparation of citalopram |
| 09/20/2001 | WO2001068629A1 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | WO2001068628A1 Method for the preparation of citalopram |
| 09/20/2001 | WO2001068627A1 Crystalline base of citalopram |
| 09/20/2001 | WO2001068619A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | WO2001068618A1 Bifunctional chelating agent |
| 09/20/2001 | WO2001068614A2 5-substituted arylpyrimidines |
| 09/20/2001 | WO2001068612A2 Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof |
| 09/20/2001 | WO2001068611A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure |
| 09/20/2001 | WO2001068609A1 1,2,3,4-tetrahydroisoquinoline derivatives |
| 09/20/2001 | WO2001068603A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 09/20/2001 | WO2001068597A1 N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them |
| 09/20/2001 | WO2001068594A1 Method for oxidizing a thioether group into a sulfoxide group |
| 09/20/2001 | WO2001068592A1 Sulfonamide derivatives |
| 09/20/2001 | WO2001068591A1 Carboxylic acid derivatives as ip antagonists |
| 09/20/2001 | WO2001068587A1 Novel crystal of stilbene derivative and process for producing the same |
| 09/20/2001 | WO2001068582A1 Novel fatty acid analogous |
| 09/20/2001 | WO2001068570A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068569A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068568A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068454A2 Pharmaceutical packaging system |
| 09/20/2001 | WO2001068235A1 Method for preparing colloidal particles in the form of nanocapsules |
| 09/20/2001 | WO2001068186A2 Use of cyanoquinolines for treating or inhibiting colonic polyps |
| 09/20/2001 | WO2001068148A1 Systemic gene delivery vehicles for the treatment of tumors |
| 09/20/2001 | WO2001068147A2 Synthetic oligonucleotides as inducers of erythroid differentiation |
| 09/20/2001 | WO2001068146A2 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/20/2001 | WO2001068145A2 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 09/20/2001 | WO2001068143A2 Immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | WO2001068142A1 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 09/20/2001 | WO2001068140A2 Opioid formulations |
| 09/20/2001 | WO2001068139A1 Formulation solubilizing water-insoluble agents and preparation method thereof |
| 09/20/2001 | WO2001068138A2 Intradermal-penetration agents for topical local anesthetic administration |
| 09/20/2001 | WO2001068136A1 Drugs for complications of diabetes and neuropathy and utilization thereof |
| 09/20/2001 | WO2001068135A2 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | WO2001068122A2 A method for reversing the immunosuppressive effects of the melanoma inhibitory activity 'mia' |
| 09/20/2001 | WO2001068117A2 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 09/20/2001 | WO2001068116A2 Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections |
| 09/20/2001 | WO2001068107A1 Hair restoration formulation |
| 09/20/2001 | WO2001068106A1 Preventives and/or remedies for hyperphosphatemia |
| 09/20/2001 | WO2001068105A1 Polysaccharidic esters of n-derivatives of glutamic acid |
| 09/20/2001 | WO2001068104A1 Compounds for the treatment of psychiatric or substance abuse disorders |
| 09/20/2001 | WO2001068103A2 Treatment of herpes infection using immunomodulatory polynucleotide sequences |
| 09/20/2001 | WO2001068102A2 Nystatin formulation having reduced toxicity |
| 09/20/2001 | WO2001068101A1 Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol |
| 09/20/2001 | WO2001068099A1 Modulation of cardiovascular injury |
| 09/20/2001 | WO2001068098A2 Cephalotaxine alkaloid combination compositions and uses thereof |
| 09/20/2001 | WO2001068097A1 Use of pyrido[3,2-e]-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction |
| 09/20/2001 | WO2001068096A2 Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders |
| 09/20/2001 | WO2001068095A1 Glycosyltransferase inhibitors |
| 09/20/2001 | WO2001068094A1 Heme oxygenase-1 inducers or induction enhancers |
| 09/20/2001 | WO2001068093A1 Use of glucosylceramide synthesis inhibitors in brain cancertherapy |
| 09/20/2001 | WO2001068092A2 Glycogen phosphorylase inhibitor |
| 09/20/2001 | WO2001068091A1 Inhibition of fungi |
| 09/20/2001 | WO2001068090A1 Microbial inhibitory compositions |
| 09/20/2001 | WO2001068089A1 Condensation derivatives of thiocolchicine and baccatin as antitumor agents |
| 09/20/2001 | WO2001068088A1 Method of chlamydia prophylaxis |
| 09/20/2001 | WO2001068086A1 Antiviral therapy |
| 09/20/2001 | WO2001068085A1 A method for stimulation of defensin production |
| 09/20/2001 | WO2001068084A1 Il-8 receptor antagonists |
| 09/20/2001 | WO2001068083A1 Use of comt inhibitors as analgesics |
| 09/20/2001 | WO2001068082A1 Treatment and/or prevention of ocular pain |
| 09/20/2001 | WO2001068081A1 Agent for treating illnesses of the tracheobronchial tract, especially chronic obstructive pulmonary disease (copd) |
| 09/20/2001 | WO2001068080A2 Neutral antagonists and use thereof in treating drug abuse |
| 09/20/2001 | WO2001068079A2 Viscoelastics for use in middle ear surgery |
| 09/20/2001 | WO2001068078A2 Immunostimulatory polynucleotide sequences for use in suppressing hepatitis virus infection |
| 09/20/2001 | WO2001068077A2 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 09/20/2001 | WO2001068076A2 D-enantiomer of dfmo and methods of use thereof for treating cancer |
| 09/20/2001 | WO2001068075A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/20/2001 | WO2001068074A2 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 09/20/2001 | WO2001068073A2 Method for improving respiratory function and inhibiting muscular degeneration |
| 09/20/2001 | WO2001068072A2 Composition for use in treatment of ocular hypertension and glaucoma |
| 09/20/2001 | WO2001068071A2 Use of natural chrysanthone compounds having antiangiogenic activity |
| 09/20/2001 | WO2001068070A2 Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis |
| 09/20/2001 | WO2001068069A2 Pharmaceutical composition comprising paracetamol |
| 09/20/2001 | WO2001068068A2 Compounds capable of binding with the cytoskeleton |
| 09/20/2001 | WO2001068067A2 Use of deramciclane for the treatment of anxiety and depression |
| 09/20/2001 | WO2001068066A2 A composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer |
| 09/20/2001 | WO2001068065A2 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease |
| 09/20/2001 | WO2001068064A2 Use of cdp-choline for the prophylactic treatment of cerebral ischemia |
| 09/20/2001 | WO2001068063A2 Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| 09/20/2001 | WO2001068058A1 Multilayer pharmaceutical product for release in the colon |
| 09/20/2001 | WO2001068055A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | WO2001068054A1 Process for the preparation of accelerated release formulations using compressed fluids |
| 09/20/2001 | WO2001068053A2 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| 09/20/2001 | WO2001068047A2 Preparation containing quinoxaline derivatives |